APA (7th ed.) Citation

P, C., Y, N., Q, W., A, H., S, M., J, W., . . . SA, K. (2024). Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials. BioRxiv : the preprint server for biology. https://doi.org/10.1101/2024.09.17.613520

Chicago Style (17th ed.) Citation

P, Chan, et al. "Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials." BioRxiv : The Preprint Server for Biology 2024. https://doi.org/10.1101/2024.09.17.613520.

MLA (9th ed.) Citation

P, Chan, et al. "Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials." BioRxiv : The Preprint Server for Biology, 2024, https://doi.org/10.1101/2024.09.17.613520.